ANKRA2

ANKRA2 is an ankyrin-repeat scaffold protein that functions as a signal-responsive transcriptional corepressor by reading short linear PxLPxI/L motifs in diverse partner proteins (PMID:22649097). Crystal structures of its ankyrin repeat domain bound to target peptides defined a tumbler-lock recognition mode in which each of the middle three repeats engages one motif residue, and showed that this interface accommodates motifs from HDAC4, HDAC5, HDAC9, megalin, and RFX5 (PMID:22649097). Through this domain ANKRA2 binds class IIa HDACs (HDAC4, HDAC5) and recruits them as corepressors: it represses CIITA-induced MHC II and HLA-DRA expression in conjunction with the paralog RFXANK (PMID:16236793), and is recruited to the AhR repressor C-terminal domain to repress CYP1A1, an interaction that depends on SUMOylation of AhRR (PMID:17949687, PMID:19251700). The same ankyrin domain can substitute for RFXANK in MHC II enhanceosome assembly by contacting RFX5, complementing RFXANK-deficient bare lymphocyte syndrome cells (PMID:15655668, PMID:16166641). Beyond immune gene regulation, ANKRA2 binds the PxLPxL motif of the 3M-syndrome protein CCDC8, linking it to the OBSL1/CUL7 ligase complex (PMID:25752541), and serves as a direct p53 target gene and a high-affinity cofactor of the tumor suppressor transcription factor RFX7, regulating RFX7-overlapping targets such as PDCD4 (PMID:31864703, PMID:39181888). HDAC4 recruitment is switched off by CaMK-driven phosphorylation of Ser350 within its PxLPxI/L motif, which disrupts ANKRA2 binding and creates a 14-3-3 docking site, coupling complex assembly to calcium signaling (PMID:16236793, PMID:22649097).

1. 2005 Medium

   Established that ANKRA2's ankyrin repeat domain physically recruits class IIa HDACs to repress MHC II transcription and that this is reversed by calcium signaling, defining ANKRA2 as a signal-responsive corepressor scaffold.

   Evidence Co-IP, reporter assays, RNAi, and nuclear export assays in cells

   PMID:16236793

   Open questions at the time

   • Did not define the structural basis of HDAC recognition
   • Endogenous physiological context of CaMK-driven export not fully mapped
2. 2005 Medium

   Showed the ankyrin repeat domain of ANKRA2 can functionally substitute for RFXANK in MHC II enhanceosome assembly and RFX5 binding, establishing ANKRA2 as a RFXANK paralog with shared recognition surface.

   Evidence Complementation in RFXANK-deficient BLS cells, domain-swap and mutagenesis, chromatin occupancy

   PMID:15655668 PMID:16166641

   Open questions at the time

   • Did not establish whether ANKRA2 substitutes for RFXANK under endogenous conditions
   • Distinct vs overlapping target genes of the two paralogs unresolved
3. 2007 Medium

   Extended ANKRA2's corepressor role beyond MHC II by identifying it as a recruiter of HDAC4/HDAC5 for AhRR-mediated repression of CYP1A1.

   Evidence Yeast two-hybrid, siRNA knockdown, reporter gene assay

   PMID:17949687

   Open questions at the time

   • Direct binding interface with AhRR not structurally defined
   • In vivo relevance to xenobiotic response not tested
4. 2009 Medium

   Revealed that AhRR SUMOylation is a prerequisite for assembling the AhRR–ANKRA2–HDAC repressor complex, adding a post-translational control layer to ANKRA2 recruitment.

   Evidence In vivo SUMOylation assays, mutagenesis, Co-IP, reporter assay

   PMID:19251700

   Open questions at the time

   • Whether SUMO acts directly on the interaction interface or indirectly is unclear
   • SUMO regulation of other ANKRA2 partners not addressed
5. 2012 High

   Defined the molecular logic of ANKRA2 partner recognition: a tumbler-lock readout of the PxLPxI/L motif by the central ankyrin repeats, and explained signal regulation by showing Ser350 phosphorylation disrupts binding while creating a 14-3-3 site.

   Evidence X-ray crystallography of peptide complexes, ITC, mutagenesis, phosphopeptide binding

   PMID:22649097

   Open questions at the time

   • Structures are of peptides, not full-length partners
   • Does not establish which motif-bearing partners predominate in a given cell type
6. 2015 High

   Identified CCDC8 as a major ANKRA2-specific (non-RFXANK) cellular partner via its PxLPxL motif, linking ANKRA2 to the OBSL1/CUL7 3M-syndrome ligase complex.

   Evidence Cellular Co-IP, X-ray crystallography of ARD–CCDC8 peptide complex, binding assays

   PMID:25752541

   Open questions at the time

   • Functional consequence of ANKRA2 in CUL7 ligase activity not established
   • No phenotypic link to 3M syndrome demonstrated for ANKRA2
7. 2019 High

   Structurally established ANKRA2 as a higher-affinity reader of the RFX7 PxLPxL motif than RFXANK, distinguishing ANKRA2's partner preference at the structural level.

   Evidence X-ray crystallography of ARD–RFX7 fragment, binding affinity measurements

   PMID:31864703

   Open questions at the time

   • Cellular consequence of preferential RFX7 binding not tested in this study
   • Whether RFX7 engagement is corepressive or coactivating left open
8. 2024 Medium

   Placed ANKRA2 in a tumor-suppressor circuit by showing it is a direct p53 target and an RFX7 cofactor that occupies the PDCD4 X-box and regulates an RFX7-overlapping, RFXANK-distinct gene set.

   Evidence Mass spectrometry of promoter-bound complex, siRNA knockdown with transcriptome analysis, reporter and p53 target validation

   PMID:39181888

   Open questions at the time

   • Whether ANKRA2 activates or represses RFX7 targets mechanistically not fully resolved
   • Tumor-suppressive phenotype in vivo not demonstrated

• How ANKRA2 partner selection is governed across cell types and how its corepressor versus RFX7-cofactor roles are integrated remains unresolved.
• No structure of ANKRA2 with full-length partners or within an intact DNA-bound enhanceosome
• Determinants choosing among HDAC4/5/9, RFX5, RFX7, CCDC8 partners in a given context unknown
• Physiological loss-of-function phenotype of ANKRA2 uncharacterized